Mayo 2012 AL Staging: Risk stratification based on Troponin, NT-proBNP, and dFLC. High thresholds reflect significant organ/clone burden.
Calculated Amyloid Stage
Median Overall Survival
Early stage disease. Favorable candidates for autologous stem cell transplant if other fitness criteria met.
Verified
Last Review: 2026-07-17
| Biomarker | Threshold |
|---|---|
| NT-proBNP | ≥ 1800 pg/mL |
| Cardiac Troponin T | ≥ 0.025 ng/mL (or Trop I ≥ 0.1) |
| dFLC (involved − uninvolved) | ≥ 18 mg/dL (180 mg/L) |
| Points | Stage | Median OS (Months) |
|---|---|---|
| 0 | Stage I | 94 |
| 1 | Stage II | 40 |
| 2 | Stage III | 14 |
| 3 | Stage IV | 5.8 |
Kumar S et al. • Journal of Clinical Oncology. 2012;30(9):989-95.
View SourceLast Comprehensive Review: 2026-07-17
Scanning Medical Journals
No new significant updates or guidelines matching this topic were found today. We will check again soon.
